Ryan Cross
@scienceboss.bsky.social
📤 56
📥 20
📝 93
Senior Science Correspondent at Endpoints News. Reach out privately on Signal: RyanCross.25
Addition Therapeutics raises $106.5M for all-RNA (no DNA required) gene insertion therapies based on retrotransposons, aka 'jumping genes' Its part of a growing trend of gene editing companies looking beyond CRISPR. My story for
@endpts.com
has the details:
endpoints.news/addition-the...
loading . . .
Berkeley startup raises $106.5M for all RNA 'jumping gene' therapies
Addition Therapeutics has raised $106.5 million for a new way to install therapeutic genes in the human genome.
https://endpoints.news/addition-therapeutics-raises-106-5m-for-all-rna-jumping-gene-therapies/
9 days ago
0
3
2
Western drugmakers are increasingly turning to Chinese investigator-initiated trials for a cheaper and faster way to test new drugs. “If they’re not doing it, they’re going to lose,” one US CEO told me.
@leileiwu.bsky.social
and I have the story for
@endpts.com
:
endpoints.news/western-gene...
loading . . .
China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in
IITs have grown increasingly popular among China researchers over the past decade, and have helped China’s fast-growing biotech sector catch up with rivals in the US and Europe. The very leniency that...
https://endpoints.news/western-genetic-medicine-makers-turn-to-chinese-investigator-initiated-trials/
11 days ago
0
1
1
Flagship's gene writing startup Tessera Therapeutics strikes $150M partnership with Regeneron for its AATD therapy, which will start clinical trials soon. CRISPR Tx and Prime Medicine are also working on similar therapies for AATD. More details in
@endpts.com
:
endpoints.news/gene-writing...
loading . . .
Gene writing startup Tessera strikes $150M partnership with Regeneron
Regeneron partners with Tessera Therapeutics in $150M deal to develop gene writing therapy for alpha-1 antitrypsin deficiency, expanding its gene editing investments.
https://endpoints.news/gene-writing-startup-tessera-strikes-150m-partnership-with-regeneron/
25 days ago
0
1
0
China biotech Zhongmou Therapeutics has developed an optogenetic gene therapy that uses an engineered alga protein to restore sight, and it hopes the approach could become a ‘one-size-fits-all’ rival to Roche's Luxturna. Read more in
@endpts.com
:
endpoints.news/chinas-zhong...
loading . . .
China biotech seeks to rewire eye cells to create ‘one-size-fits-all’ rival to Luxturna
Wuhan-based Zhongmou Therapeutics reports promising results from gene therapy trial for retinitis pigmentosa, with 7 of 9 blind patients showing vision improvement.
https://endpoints.news/chinas-zhongmou-seeks-to-create-a-one-size-fits-all-rival-to-luxturna/
30 days ago
0
1
0
There's been a death in a
#CRISPR
study, something the field has long feared. A man who was recently hospitalized with liver injury a few weeks after receiving Intellia's experimental gene editing therapy died last night. More details in my story for
@endpts.com
endpoints.news/patient-in-i...
loading . . .
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury
Patient in 80s dies after receiving Intellia Therapeutics' CRISPR therapy nex-z for ATTR. Death follows liver injury; exact cause unclear. CEO John Leonard announces trial pause.
https://endpoints.news/patient-in-intellia-crispr-trial-dies-after-being-hospitalized-with-liver-injury/
about 2 months ago
0
0
1
Arena BioWorks shuts down after investors pull plug on big bold bet to reinvent biotech, founder Stuart Schreiber confirmed to me. He pointed to biotech macro conditions and also investors seeking bigger returns on AI and tech. Details in my story for
@endpts.com
:
endpoints.news/arena-biowor...
loading . . .
Arena BioWorks shuts down after investors pull plug on bold bid to reinvent biotech model
Arena BioWorks, backed by $500M from billionaires, shuts down after less than 2 years. Founder Stuart Schreiber cites biotech market conditions and investors seeking AI opportunities.
https://endpoints.news/arena-bioworks-shuts-down-after-investors-pull-plug-on-bid-to-reinvent-biotech/
about 2 months ago
0
0
0
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T.
@endpts.com
-
endpoints.news/jennifer-dou...
loading . . .
Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T
Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.
https://endpoints.news/jennifer-doudna-startup-azalea-therapeutics-launches-with-82m/
about 2 months ago
0
6
4
The scientists behind Baby KJ’s life-saving CRISPR therapy have a plan to help more patients. Join me and
@drewsnews.bsky.social
at 9:45 for a conversation with UPenn's Kiran Musunuru and CHOP's Rebecca Ahrens-Nicklas to learn more!
@endpts.com
endpoints.news/post-hoc-liv...
loading . . .
Watch at 9:45 a.m.: Meet the scientists behind Baby KJ’s life-saving CRISPR therapy
U Penn's Musunuru and CHOP's Ahrens-Nicklas discuss plans to expand Baby KJ's custom CRISPR therapy for rare genetic diseases into an FDA-approved treatment.
https://endpoints.news/post-hoc-live-meet-the-scientists-behind-baby-kjs-life-saving-crispr-therapy/
about 2 months ago
1
1
1
DNA-chopping enzyme that breaks up NETs (neutrophil extracellular traps) may offer new way to fight autoimmune disease, early data from
#Neutrolis
suggest. The company has raised $50M from Morningside. Read more in my latest exclusive for
@endpts.com
.
#ACR2025
endpoints.news/dna-chopping...
loading . . .
Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest
Neutrolis tests enzyme therapy targeting neutrophil extracellular traps (NETs) in Phase 1 trial, showing promise for autoimmune diseases. Drug cleared symptoms in teen with DNASE1L3 deficiency.
https://endpoints.news/dna-chopping-enzyme-that-breaks-up-nets-may-offer-new-way-to-fight-autoimmune-disease-early-data-from-neutrolis-suggest/
about 2 months ago
0
1
0
Causeway Therapeutics had developed a synthetic
#microRNA
therapy that it hopes will heal injured tendons. The company shared its Phase 2 results with me and its plans to raise a large series A for bigger trials. Read more in my latest story for
@endpts.com
-
endpoints.news/microrna-sta...
loading . . .
Exclusive: Scottish microRNA startup claims signs of success in Phase 2 tendinopathy study
Causeway Therapeutics' microRNA drug for tennis elbow missed primary endpoint in Phase 2, but showed promise in properly injected patients. Plans Phase 3 amid $150M+ fundraising.
https://endpoints.news/microrna-startup-causeway-targets-raise-after-results-of-tendinopathy-study/
about 2 months ago
0
2
1
Halda Therapeutics has made small molecule drugs called RIPTACs that inhibit an essential protein cells need to live, but only in the presence of a second protein that is primarily found in cancer cells. My story for
@endpts.com
on Halda's first clinical data:
endpoints.news/halda-reveal...
loading . . .
Halda's first clinical test of RIPTAC drugs suggests a safer way to kill cancer
Halda Therapeutics reports promising data for HLD-0915 in prostate cancer trial, with 59% of patients showing PSA reduction of 50%+ after two treatment cycles.
https://endpoints.news/halda-reveals-first-clinical-data-of-riptac-drug-in-prostate-cancer/
2 months ago
0
1
0
Remix Therapeutics has revealed the first clinical data of its "mRNA degrader," a small molecule drug that forces the inclusion of a 'kill switch' into mRNA, leading to its destruction. Its first drug targets the undruggable oncogene MYB. Read more in
@endpts.com
:
endpoints.news/remix-reveal...
loading . . .
Remix Therapeutics reveals first signs of tumor shrinkage with its small molecule mRNA degrader
Remix Therapeutics, which is developing a new way to shut down the expression of cancer-causing genes, has seen the first signs of success in a rare salivary gland cancer.
https://endpoints.news/remix-reveals-first-signs-of-tumor-shrinkage-with-small-molecule-mrna-degrader/
2 months ago
0
1
0
Arcturus announces mixed results of its inhaled
#mRNA
therapy designed to produce CFTR protein in cystic fibrosis patients. And the FDA is asking for more data before reviewing its
#Covid-19
vaccine for approval. My story for
@endpts.com
has the details:
endpoints.news/arcturus-ann...
loading . . .
Arcturus’ stock halved after mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delay
The biotech's ambitious attempt to restore the critical protein that is broken or missing in people with cystic fibrosis has yielded mixed results in an ongoing Phase 2 study.
https://endpoints.news/arcturus-announces-mixed-results-of-mrna-cystic-fibrosis-therapy-covid-19-vaccine-delay/
2 months ago
0
1
0
Starna Therapeutics, a Chinese biotech startup founded by mRNA and LNP scientists, has raised a $44M series B to advance its in vivo CAR-T programs after promising, albeit early, results in lupus and cancer patients. Read more in my exclusive story for
@endpts.com
:
endpoints.news/starna-thera...
loading . . .
Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data
Chinese biotech Starna Therapeutics reports early success in clinical tests of in vivo CAR-T therapy, eliminating B cells in lupus and lymphoma patients, raising $44M Series B from LYFE Capital and ot...
https://endpoints.news/starna-therapeutics-raises-44m-to-advance-in-vivo-car-t-programs-after-early-clinical-data/
2 months ago
0
0
0
#CRISPR
Therapeutics recently debuted a new gene editing tool called SyNTase editing that it described as 'a significant advance' over prime editing. Prime Medicine disagrees. My latest story for
@endpts.com
digs into the details:
endpoints.news/crispr-thera...
loading . . .
CRISPR Therapeutics says its new gene editing tool is 'a significant advance' over prime editing. Prime Medicine disagrees
CRISPR Therapeutics unveils SyNTase editor tool, plans AATD trial for 2026. Prime Medicine disputes novelty, suggesting similarities to their prime editing tech. Licensing talks reported.
https://endpoints.news/crispr-therapeutics-says-its-new-gene-editing-tool-is-a-significant-advance-over-prime-editing-prime-medicine-disagrees/
2 months ago
0
1
0
British startup Genomics has spent over a decade amassing a human genotype-phenotype database from over 25,000 GWAS studies. Now it is launching a new product to get that data, and software to analyze it, into the hands of drug developers. My story for
@endpts.com
:
endpoints.news/british-star...
loading . . .
British startup Genomics launches business to help drug developers
Oxford spinout Genomics launches Mystra, an AI tool for drug development, using vast genetic database. CEO Peter Donnelly courts pharma leaders from Eli Lilly, Novartis, Roche & Takeda.
https://endpoints.news/british-startup-genomics-launches-business-to-help-drug-developers/
2 months ago
0
2
0
Exclusive for
@endpts.com
: Lipid nanoparticle startup Liberate Bio has emerged with $31M in seed funding from Khosla Ventures and plans to test in vivo cell therapies targeting macrophages and monocytes in the clinic in 2026.
endpoints.news/exclusive-li...
loading . . .
Exclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in vivo cell therapies
Liberate Bio raises $31M seed funding from Khosla Ventures, developing in vivo cell therapy using monocytes and macrophages to fight cancer and other diseases.
https://endpoints.news/exclusive-lipid-nanoparticle-startup-emerges-with-31m-from-khosla-for-in-vivo-cell-therapies/
2 months ago
0
1
0
The Yale spinout Bexorg has raised a $23M series A for its cutting-edge and unconventional approch to preclinical research: testing drugs on ‘rebooted’ human brains from organ donors. My story for
@endpts.com
has the details:
endpoints.news/bexorg-raise...
loading . . .
Yale spinout raises $23M to test drugs on ‘rebooted’ human brains from organ donors
Bexorg has collected $23 million in a Series A raise to scale up its human brain experiments, bringing its total funding to $42.5 million, the startup announced Wednesday.
https://endpoints.news/bexorg-raises-23m-to-test-drugs-on-rebooted-human-brains-from-organ-donors/
2 months ago
1
2
1
#ESGCT2025
: A woman who was previously ineligible for
@genethonfr.bsky.social
's Crigler–Najjar syndrome gene therapy due to pre-existing immunity to AAV8 got the treatment after Hansa Bio's antibody-chopping drug imlifidase cleared the way. Read more in
@endpts.com
:
endpoints.news/new-study-su...
loading . . .
Person previously ineligible for gene therapy granted treatment after antibody-chopping drug clears the way
Study shows Hansa's Idefirix helps deliver Genethon's AAV8 gene therapy GNT003 in previously ineligible Crigler-Najjar patient by clearing antibodies, reports Do Cao at ESGCT.
https://endpoints.news/new-study-suggests-patients-with-anti-aav-antibodies-may-still-receive-gene-therapy/
3 months ago
0
4
2
At
#ESGCT2025
, Mammoth Bio presented the first monkey data of its lead program, a gene editing therapy that uses its small Cas-Phi enzyme to target APOC3 for triglyceride reduction. A clinical trial is planed for the second half 2026. More in my story for
@endpts.com
:
endpoints.news/mammoth-bios...
loading . . .
Mammoth Biosciences is getting closer to finding out if its big bet on tiny CRISPR enzymes will pay off
Mammoth Biosciences reveals monkey data for CRISPR therapy targeting APOC3 gene to lower triglycerides, with CEO Trevor Martin planning clinical trials in 2026.
https://endpoints.news/mammoth-biosciences-plans-first-trial-of-triglyceride-lowering-gene-editing-therapy/
3 months ago
0
1
0
At
#ESGCT2025
, Seppo Ylä-Herttuala from the University of Eastern Finland reported success in Phase 2b study of a gene therapy that uses a surgical technique to inject adenoviruses containing the VEGF-D gene into ischemic heart tissue. My story for
@endpts.com
:
endpoints.news/finnish-rese...
loading . . .
Finnish researchers report success in mid-stage study of heart disease gene therapy
Researchers from the University of Eastern Finland said a gene therapy for people with refractory angina, a form of chronic chest pain that persists despite treatment, was successful in a Phase 2b stu...
https://endpoints.news/finnish-researchers-report-success-in-mid-stage-study-of-heart-disease-gene-therapy/
3 months ago
0
2
0
At
#ESGCT2025
, the scientists behind Baby KJ’s custom
#CRISPR
gene editing therapy said they are planning a clinical trial to help more children and turn the one-off drug into an approvable, repeatable procedure. My story for
@endpts.com
has more details. -
endpoints.news/qa-scientist...
loading . . .
Q&A: The scientists behind Baby KJ’s custom CRISPR drug are planning a trial to help more children
Scientists led by Kiran Musunuru plan clinical trial for custom gene editing therapies, following success with
https://endpoints.news/qa-scientists-behind-baby-kjs-custom-crispr-drug-are-planning-to-help-more-children/
3 months ago
0
3
0
Arbor Biotechnologies has partnered with Chiesi Group in
#CRISPR
gene editing deal worth up to $2 billion, just 10 weeks after announcing it had dosed the first patient in its PH1 trial. Next up for Arbor: a trio of ALS therapies. Read more in
@endpts.com
-
endpoints.news/arbor-partne...
loading . . .
Arbor partners with Chiesi Group in gene editing deal with potential $2B future payments
Chiesi Group partners with Arbor Biotechnologies in CRISPR deal worth up to $2B for PH1 therapy and rare liver diseases, following first patient dosing in clinical trial.
https://endpoints.news/arbor-partners-with-chiesi-group-in-gene-editing-deal/
3 months ago
0
1
0
I am heading to Spain next week to cover the
#ESGCT2025
meeting for
@endpts.com
. If you're presenting new cell therapy, gene therapy, gene editing or RNA therapy research at the meeting, or just want to meet, reach out!
3 months ago
1
1
1
The French biotech EG 427 has made a gene therpay based on a herpesvirus vector that delivers a botulinum toxin to sensory neurons to reduce urinary incontinence by 88% in spinal cord injury patients. More details on the data and science in my exclusive for @endpts -
endpoints.news/exclusive-fr...
loading . . .
Exclusive: French startup's gene therapy dramatically reduces urinary incontinence in spinal cord injury patients
EG 427's gene therapy shows 88% reduction in urinary incontinence for spinal cord injury patients at 12 weeks, using herpesvirus vector to deliver botulinum toxin F to bladder.
https://endpoints.news/exclusive-french-startups-gene-therapy-dramatically-reduces-urinary-incontinence-in-spinal-cord-injury-patients/
3 months ago
0
2
1
In 2023, Biogen said it would deprioritize its early stage gene therapy research, but a small team of scientists continued working on next-gen AAV capsids. Now Biogen has cut its remaining AAV work. Read more in my exclusive for
@endpts.com
-
endpoints.news/biogen-calls...
loading . . .
Exclusive: Biogen calls it quits on AAV gene therapy, again
Biogen is ending its gene therapy work that relies on adeno-associated viruses, or AAVs, the company confirmed to Endpoints News, making it the latest pharma to walk away from the viral-based delivery...
https://endpoints.news/biogen-calls-it-quits-on-aav-gene-therapy-again/
3 months ago
0
1
0
Feng Zhang's startup Aera Therapeutics has announced an in vivo CAR-T therapy for autoimmune disease as its lead program, and plans to be in clinical trials in mid-2026. Read more about that program, and two more at Aera, in my exclusive for
@endpts.com
-
endpoints.news/aera-therape...
loading . . .
Exclusive: Aera Therapeutics jumps into in vivo CAR-T race with trial planned for 2026
Aera Therapeutics is the latest company hoping that a simple infusion can reprogram the immune system to wipe out errant cells responsible for autoimmune disease. It's planning on testing the in vivo ...
https://endpoints.news/aera-therapeutics-jumps-into-in-vivo-car-t-race-with-trial-planned-for-2026/
3 months ago
0
1
0
One of my favorite rituals at @endpts is picking our annual list of the most promising startups pushing science and medicine forward. Hundreds are nominated, we seriously debate 40-50 of them, and we whittle it down to the Endpoints 11. The list is out!
endpoints.news/the-2025-win...
loading . . .
The Endpoints 11 list: Meet the most exciting biotech startups of 2025
Announcing the 2025 Endpoints 11 winners — the most exciting, high-risk, high-reward biotech startups of the year.
https://endpoints.news/the-2025-winners-of-the-endpoints-11-biotechs-most-exciting-startups/
3 months ago
1
2
0
I spoke with
#LaskerAward
winner Michael Welsh from the University of Iowa about how he helped unravel the molecular mechanisms of
#CysticFibrosis
that laid the foundation for Vertex's life-saving drugs for the once fatal disease. Read the interview on
@endpts.com
:
endpoints.news/a-conversati...
loading . . .
Q&A: Lasker Award winner Michael Welsh on the science that led to life-saving cystic fibrosis drugs
Scientists Welsh, González, and Negulescu win Lasker Award for cystic fibrosis research, including Welsh's molecular insights and Vertex's Trikafta drug development.
https://endpoints.news/a-conversation-with-lasker-award-winner-michael-welsh-on-life-saving-cystic-fibrosis-drugs/
4 months ago
0
0
0
Chinese
#CRISPR
company YolTech Therapeutics has raised a $45M series B as it plans for its first Phase 3 study in ATTR, the same genetic disease that US-based Intellia recently began a pair of Phase 3 studies in. Read more in my exclusive for
@endpts.com
:
endpoints.news/chinese-cris...
loading . . .
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
https://endpoints.news/chinese-crispr-company-yoltech-raises-45m-as-it-plans-for-first-phase-3-study/
4 months ago
0
1
0
China biotech Epigenic Therapeutics raises $60M to test
#CRISPR
#epigenetic
therapies for HBV in Phase 1/2 trial, competing with US startups nChroma and Tune. Read more from my exclusive interview with Epigenic CEO Bob Zhang in my story for
@endpts.com
endpoints.news/china-biotec...
loading . . .
China biotech Epigenic raises $60M to test CRISPR epigenetic therapies
Epigenic Therapeutics raises $60M Series B for CRISPR-based hepatitis B therapy, with CEO Bob Zhang leading clinical trials in New Zealand, China and US through 2027.
https://endpoints.news/china-biotech-epigenic-raises-60m-to-test-crispr-epigenetic-therapies/
4 months ago
0
2
0
Neuropsych startup Sensorium, founded by Mass General and Harvard scientists, has raised $25M for a Phase 1 study of a new plant-derived drug for anxiety. CEO Jacob Hooker told me about the drug's mechanism for the first time in my exclusive story for
@endpts.com
:
endpoints.news/sensorium-ra...
loading . . .
Exclusive: Sensorium raises $25M to test succulent-derived drug for anxiety
Sensorium, a startup founded by scientists from Mass General and Harvard in 2021 to look for new brain drugs from plants and fungi, has raised a $25 million series A extension, the company told Endpoi...
https://endpoints.news/sensorium-raises-25m-for-clinical-tests-of-succulent-derived-drug-for-anxiety/
4 months ago
0
0
0
Gameto, a startup looking to disrupt the in vitro fertilization industry with stem cell technology from George Church's lab, has raised $44 million in Series C financing for its Phase 3 study. My story for
@endpts.com
has the details:
endpoints.news/fertility-st...
loading . . .
Fertility startup Gameto raises $44M to fund Phase 3 study of stem cell IVF therapy
The new funding will allow Gameto to finish a Phase 3 study of its therapy in 500 people looking to conceive via in vitro fertilization.
https://endpoints.news/fertility-startup-gameto-raises-44m-to-fund-phase-3-study-of-stem-cell-ivf-therapy/
5 months ago
0
1
1
After promising proof of concept data from a Phase 1 study earlier this year, Strand Therapeutics has raised $153 million series B funding to test its
#mRNA
cancer therapies encoding the potent immune-stimulating protein IL-12. Read more in Endpoints News:
endpoints.news/strand-thera...
loading . . .
Strand Therapeutics nabs $153M to test mRNA cancer therapies
Strand Therapeutics, a startup based on research from MIT, has managed to pull off one of the largest raises for an mRNA-focused biotech in recent years.
https://endpoints.news/strand-therapeutics-nabs-153m-to-test-mrna-cancer-therapies/
5 months ago
0
1
0
The session at
#AAIC25
on Roche's next-gen
#Alzheimers
drug
#trontinemab
was jam packed and despite one patient's death, the excitement for this drug was palpable. Read more about the dramatic amyloid reduction and surprisingly low ARIA in
@endpts.com
-
endpoints.news/roche-double...
loading . . .
Roche doubles down on its Alzheimer's ambitions as next-gen amyloid-lowering drug excites scientists
Roche revealed the latest cut of data from its closely-watched Phase 1/2 study of trontinemab, an amyloid-targeting antibody designed to latch onto receptors that yank it across the protective blood-b...
https://endpoints.news/roche-doubles-down-on-its-alzheimers-ambitions-as-next-gen-amyloid-lowering-drug-excites-scientists/
5 months ago
0
1
1
Orbital Therapeutics, a circular RNA startup that raised $270M for nex-gen RNA drugs in 2023, revealed its first program and first preclinical data for an in vivo CAR-T cell therapy for autoimmune disease. More details in my story for
@endpts.com
-
endpoints.news/circular-rna...
loading . . .
Exclusive: Circular RNA startup Orbital unveils first monkey data as it enters in vivo CAR-T cell therapy race
Orbital Therapeutics reveals first preclinical data for circular RNA-based in vivo CAR-T therapy for autoimmune diseases, showing B cell elimination in monkeys with two infusions.
https://endpoints.news/circular-rna-startup-orbital-unveils-first-monkey-data-as-it-enters-in-vivo-car-t-cell-therapy-race/
5 months ago
0
3
1
David Baker’s lab
@uwproteindesign.bsky.social
uses AI to catch nature’s squirmiest proteins, the notoriously undruggable intrinsically disordered proteins. I covered the new methods, which could have implications in cancer, diabetes, pain and more for
@endpts.com
-
endpoints.news/david-bakers...
loading . . .
David Baker’s lab uses AI to help catch nature’s squirmiest proteins
David Baker reveals AI strategies to develop proteins binding to intrinsically disordered proteins (IDPs), enabling potential drug development for previously
https://endpoints.news/david-bakers-lab-uses-ai-to-help-catch-natures-squirmiest-proteins/
5 months ago
0
1
0
Sail Bio, the Flagship company that combined the circular RNA startup Laronde and nanoparticle startup Senda, just cut its staff by 30%. The CEO and CMO left earlier this year. Now the CSO and heads of platform, legal and HR are gone too. Read more in
@endpts.com
endpoints.news/sail-bio-cut...
loading . . .
Flagship's circular RNA company Sail Bio cuts staff by 30% and trims leadership team
Sail Biomedicines cuts 29% of workforce (36 employees) and loses executives including CSO Trevor Hallam as it focuses on in vivo CAR-T therapy for autoimmune disease
https://endpoints.news/sail-bio-cuts-staff-by-30-and-trims-leadership-team/
5 months ago
0
0
0
The FDA approved a new dosing of Lilly’s
#Alzheimers
drug
#Kisunla
to lower brain swelling risks known as ARIA-E, based on a new Phase 3 study where modified dosing caused ARIA-E in 14% of patients compared to 24% on original dosing. More in my story for
@endpts.com
endpoints.news/fda-approves...
loading . . .
FDA approves new dosing of Lilly’s Alzheimer’s drug to lower brain swelling risks
Lilly's Alzheimer's drug Kisunla gets FDA approval for new dosing regimen reducing brain swelling risk by 41%.
https://endpoints.news/fda-approves-new-dosing-of-lillys-alzheimers-drug-kisunla-to-lower-brain-swelling-risks/
6 months ago
0
2
0
A new CRISPR Cures center, fuded by $20M from
@chanzuckerberg.bsky.social
and led by
@urnov.bsky.social
, will create 8 custom therapies for patients in the next 3 years. “Our goal is to aggressively walk the walk of CRISPR platformization,” Urnov told me.
@endpts.com
endpoints.news/crispr-cures...
loading . . .
'CRISPR Cures' center launches with $20M to make customized gene editing therapies
Scientists seeking to make personalized gene editing therapies a reality for more people have launched a new initiative to develop cures for the rarest of diseases left behind by drug companies.
https://endpoints.news/crispr-cures-center-launches-to-make-custom-gene-editing-therapies/
6 months ago
0
12
4
It's a tough time to be a vaccine startup, but Centivax CEO Jacob Glanville has raised $45M for a universal flu shot made with 22 different mRNA strands encoding viral strains back to 1918. A clinical trial starts next year. My story for
@endpts.com
has all the details
endpoints.news/startup-rais...
loading . . .
Exclusive: Startup raises $45M for universal flu vaccines made with mRNA
It’s not an easy time to raise money for vaccine development, especially shots that rely on mRNA technology. But against all odds, one startup has cinched $45 million to begin ...
https://endpoints.news/startup-raises-45m-for-universal-flu-vaccines-made-with-mrna/
6 months ago
0
1
0
reposted by
Ryan Cross
Endpoints News
6 months ago
Exclusive: Khosla Ventures leads $12M seed for Circulate Health, a startup offering $8K-$10K plasma exchange sessions at longevity clinics to boost healthspan.
loading . . .
Exclusive: Khosla Ventures backs startup selling ‘therapeutic plasma exchange’ at longevity clinics
Circulate Health, a startup offering a potential anti-aging procedure, has raised $12 million in seed funding led by Khosla Ventures, the companies told Endpoints News in exclusive interviews.
https://endpoints.news/khosla-ventures-backs-therapeutic-plasma-exchange-startup-circulate-health/?utm_source=Bluesky&utm_medium=organic_social&utm_campaign=editorial&utm_content=
1
0
1
If you are at
#BIO2025
this morning, stop by room 251 at 9:00 am for my discussion with leaders from Aera, Alnylam, Intellia and Regeneron on "Platform Power" in genetic medicines.
6 months ago
0
1
0
In another interesting alternative to animal models, the organoid startup Parallel Bio has raised $21 million to test drugs and vaccines in its lymph node-in-a-dish technology, sourced from 100 human tissue donors. Read more in my exclusive story for
@endpts.com
-
endpoints.news/organoid-sta...
loading . . .
Exclusive: Organoid startup raises $21M to test drugs and vaccines in human lymph nodes-in-a-dish
Parallel Bio, a startup that figured out how to grow miniature human lymph nodes in a dish, has raised $21 million in Series A funding for its alternative to animal models.
https://endpoints.news/organoid-startup-raises-21m-to-test-drugs-and-vaccines-in-human-lymph-nodes-in-a-dish/
7 months ago
0
1
0
Most biotech labs look the same, but I recently saw something incredible during my visit to Bexorg: a human brain floating in a bucket, hooked up to a complex machine to keep its constituent cells alive. Read more in my exclusive deep dive for
@endpts.com
:
endpoints.news/rebooting-de...
loading . . .
Exclusive: Rebooting dead human brains, a biotech startup seeks to reinvent early drug testing work
Startup Bexorg, led by Zvonimir Vrselja, keeps human brains alive to test drugs. Their BrainEx system sustains brain cells for 24 hours to improve drug development and reduce animal testing.
https://endpoints.news/rebooting-dead-human-brains-biotech-seeks-to-reinvent-drug-testing-work/
7 months ago
1
1
0
Casma Therapeutics raised more than $150 million since it launched in 2018 to develop drugs that target autophagy. It's presenting its first preclinical data in Gaucher's disease this week, but recently trimmed its staff to 5 employees. Read more in
@endpts.com
endpoints.news/after-layoff...
loading . . .
Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug
Casma Therapeutics reveals preclinical data for TRPML1 agonist that enhances cellular waste removal. Plans 2026 trials for Gaucher's/Parkinson's patients, but faces funding needs.
https://endpoints.news/after-layoffs-casma-eyes-path-to-clinic-with-autophagy-boosting-drug/
7 months ago
0
0
0
reposted by
Ryan Cross
Jared Whitlock
7 months ago
DNA giant Illumina spawned an ecosystem. Now its former employees are both its customers and fiercest competitors. My latest is an in-depth look at a different kind of corporate lineage story, via
@endpts.com
endpts.com/how-illumina...
loading . . .
DNA giant Illumina spawned an ecosystem of competitors and customers
For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new frontiers in biology, medicine and ...
https://endpts.com/how-illuminas-ex-employees-became-its-customers-and-competitors/
0
3
2
AI bio could learn a few things from overhyped history of CRISPR. A smart tale from
@andrewedunn.bsky.social
in his latest Post-Hoc for
@endpts.com
:
endpts.com/post-hoc-ai-...
loading . . .
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, responding to DeepMind CEO's disease cure claims.
https://endpts.com/post-hoc-ai-bio-needs-to-heed-the-overhyped-history-of-crispr/
7 months ago
0
1
0
Here's a wild idea: attach a cocaine-like molecule to the surface of a torn-up adenovirus and inject it in chronic drug users to help them develop antibodies that prevent cocaine from reaching the brain. I have the details of the first clinical results in
@endpts.com
endpts.com/researchers-...
loading . . .
Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study
Weill Cornell Medicine study shows cocaine vaccine triggers antibodies & reduces drug use in small trial, but effects modest. Monthly shots helped 21 addicts, says researcher Ronald Crystal.
https://endpts.com/researchers-reveal-mixed-results-from-vaccine-for-cocaine-addiction/
7 months ago
0
3
1
Crispr Therapeutics surprised me yesterday when it partnered with an siRNA company. After all, isn't CRISPR supposed to do anything that siRNA can do, only permanently? I talked to CEO Sam Kulkarni about why even he doesn't think gene editing is a panacea.
@endpts.com
endpts.com/crispr-thera...
loading . . .
CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer
The gene editing company CRISPR Therapeutics surprisingly struck a deal with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA drug for blood clotting di...
https://endpts.com/crispr-therapeutics-partners-with-sirna-company-showing-that-gene-editing-isnt-the-only-answer/
7 months ago
0
3
1
Load more
feeds!
log in